Piscataway, NJ, June 16, 2025 – Camber announces the launch of Mycophenolate Mofetil Tablets, USP (generic for CellCept®), further expanding its immunosuppressant portfolio following the April 2025 launch of Mycophenolate Mofetil Capsules. With over 48,000 organ transplants performed annually in the U.S.—and more than 100,000 patients still on waiting lists—Camber remains committed to providing critical therapies that support long-term organ acceptance and improve transplant outcomes.
Mycophenolate Mofetil Tablets, USP are an antimetabolite immunosuppressant indicated for the prophylaxis of organ rejection in adult and pediatric recipients 3 months of age and older of allogeneic kidney, heart or liver transplants, in combination with other immunosuppressants.
Mycophenolate Mofetil Tablets, USP are available in 500 mg strength, packaged in bottles of 100 and 500 tablets.
To find out more information on Mycophenolate Mofetil Tablets, USP, please visit: www.camberpharma.com/mycophenolatetablets
Camber Pharmaceuticals is a fully integrated pharmaceutical company. Its parent company, Hetero, of Hyderabad, India, is one of the world’s leading API and finished dose manufacturers. Camber is committed to bringing the highest quality generic pharmaceuticals to consumers and improving quality of life through cost-effective medications.
